Prokopenko, I., McCarthy, M.I. & Lindgren, C.M. Type 2 diabetes: new genes, new understanding. Trends Genet. 24, 613–621 (2008).
Bouatia-Naji, N. et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat. Genet. 41, 89–94 (2009).
Bouatia-Naji, N. et al. A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science 320, 1085–1088 (2008).
Chen, W.M. et al. Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J. Clin. Invest. 118, 2620–2628 (2008).
Prokopenko, I. et al. Variants in MTNR1B influence fasting glucose levels. Nat. Genet. 41, 77–81 (2009).
Dupuis, J. et al. Novel genetic loci implicated in fasting glucose homeostasis and their impact on related metabolic traits. Nat. Genet. advance online publication, doi:10.1038/ng.520 (17 January 2010).
Ceriello, A. et al. Postprandial glucose regulation and diabetic complications. Arch. Intern. Med. 164, 2090–2095 (2004).
Qiao, Q., Tuomilehto, J. & Borch-Johnsen, K. Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 46 Suppl 1, M17–M21 (2003).
Meigs, J.B., Nathan, D.M., D'Agostino, R.B. Sr. & Wilson, P.W. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 25, 1845–1850 (2002).
Schousboe, K. et al. Twin study of genetic and environmental influences on glucose tolerance and indices of insulin sensitivity and secretion. Diabetologia 46, 1276–1283 (2003).
Orho-Melander, M. et al. Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57, 3112–3121 (2008).
Grant, S.F. et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 38, 320–323 (2006).
Matthews, D.R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985).
Gautier, J.F., Choukem, S.P. & Girard, J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab. 34 Suppl 2, S65–S72 (2008).
Nauck, M.A. et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 63, 492–498 (1986).
Ahren, B. & Pacini, G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur. J. Endocrinol. 150, 97–104 (2004).
Lyssenko, V. et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J. Clin. Invest. 117, 2155–2163 (2007).
Laakso, M. et al. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia 51, 502–511 (2008).
Miyawaki, K. et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. USA 96, 14843–14847 (1999).
Almind, K. et al. Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells. Diabetologia 41, 1194–1198 (1998).
Kubota, A. et al. Identification of two missense mutations in the GIP receptor gene: a functional study and association analysis with NIDDM: no evidence of association with Japanese NIDDM subjects. Diabetes 45, 1701–1705 (1996).
Nitz, I. et al. Association analyses of GIP and GIPR polymorphisms with traits of the metabolic syndrome. Mol. Nutr. Food Res. 51, 1046–1052 (2007).
Hardy, J. & Singleton, A. Genomewide association studies and human disease. N. Engl. J. Med. 360, 1759–1768 (2009).
Drucker, D.J. The role of gut hormones in glucose homeostasis. J. Clin. Invest. 117, 24–32 (2007).
Leech, C.A., Castonguay, M.A. & Habener, J.F. Expression of adenylyl cyclase subtypes in pancreatic beta-cells. Biochem. Biophys. Res. Commun. 254, 703–706 (1999).
Velayos-Baeza, A., Vettori, A., Copley, R.R., Dobson-Stone, C. & Monaco, A.P. Analysis of the human VPS13 gene family. Genomics 84, 536–549 (2004).
Sparso, T. et al. The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 51, 70–75 (2008).
Holst, J.J., Gromada, J. & Nauck, M.A. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 40, 984–986 (1997).
Meier, J.J. et al. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 50, 2497–2504 (2001).
Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39, 906–913 (2007).
Li, Y., Ding, J. & Abecasis, G. Mach 1.0: rapid haplotype reconstruction and missing genotype inference. Am. J. Hum. Genet. S79, 2290 (2006).
Pe′er, I. et al. Evaluating and improving power in whole-genome association studies using fixed marker sets. Nat. Genet. 38, 663–667 (2006).
Matthews, J.N., Altman, D.G., Campbell, M.J. & Royston, P. Analysis of serial measurements in medical research. Br. Med. J. 300, 230–235 (1990).
Valle, T. et al. Mapping genes for NIDDM. Design of the Finland-United States Investigation of NIDDM Genetics (FUSION) Study. Diabetes Care 21, 949–958 (1998).
Nauck, M.A. & El-Ouaghlidi, A. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia 48, 608–611 (2005).